Bulletin
Investor Alert

New York Markets Open in:

Seattle Genetics Inc.

NAS: SGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 12, 2019, 4:50 p.m.

/zigman2/quotes/203326163/composite

$

112.26

Change

0.00 0.00%

Volume

Volume 122,660

Quotes are delayed by 20 min

/zigman2/quotes/203326163/composite

Previous close

$ 111.34

$ 112.26

Change

+0.92 +0.83%

Day low

Day high

$110.40

$112.76

Open

52 week low

52 week high

$51.50

$122.36

Open

Insider Actions for Seattle Genetics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/09/2019 Clay B. Siegall
President and CEO; Director
500   Disposition at $117.76 per share. 58,880
12/09/2019 Clay B. Siegall
President and CEO; Director
1,800   Disposition at $116.98 per share. 210,564
12/09/2019 Clay B. Siegall
President and CEO; Director
2,111   Disposition at $115.53 per share. 243,883
12/09/2019 Clay B. Siegall
President and CEO; Director
6,734   Disposition at $114.59 per share. 771,649
12/09/2019 Clay B. Siegall
President and CEO; Director
17,327   Disposition at $114.08 per share. 1,976,664
12/09/2019 Clay B. Siegall
President and CEO; Director
500   Derivative/Non-derivative trans. at $12 per share. 6,000
12/09/2019 Clay B. Siegall
President and CEO; Director
1,800   Derivative/Non-derivative trans. at $12 per share. 21,600
12/09/2019 Clay B. Siegall
President and CEO; Director
2,111   Derivative/Non-derivative trans. at $12 per share. 25,332
12/09/2019 Clay B. Siegall
President and CEO; Director
6,734   Derivative/Non-derivative trans. at $12 per share. 80,808
12/09/2019 Clay B. Siegall
President and CEO; Director
17,327   Derivative/Non-derivative trans. at $12 per share. 207,924
12/06/2019 Vaughn B. Himes
Chief Technical Officer
1,049   Disposition at $117.61 per share. 123,372
12/06/2019 Vaughn B. Himes
Chief Technical Officer
6,951   Disposition at $117.09 per share. 813,892
12/06/2019 Vaughn B. Himes
Chief Technical Officer
8,000   Derivative/Non-derivative trans. at $12 per share. 96,000
11/25/2019 Roger D. Dansey
Chief Medical Officer
5,000   Disposition at $121.48 per share. 607,400
11/25/2019 Roger D. Dansey
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $65.11 per share. 325,550
11/21/2019 Srinivas Akkaraju
Director
4,942   Disposition at $120.46 per share. 595,313
11/21/2019 Srinivas Akkaraju
Director
12,558   Disposition at $119.51 per share. 1,500,806
11/21/2019 Srinivas Akkaraju
Director
4,942   Derivative/Non-derivative trans. at $19.02 per share. 93,996
11/21/2019 Srinivas Akkaraju
Director
12,558   Derivative/Non-derivative trans. at $19.02 per share. 238,853
11/18/2019 Marc E. Lippman
Director
17,500   Disposition at $115.43 per share. 2,020,025
11/18/2019 Marc E. Lippman
Director
17,500   Disposition at $116.17 per share. 2,032,975
11/18/2019 Roger D. Dansey
Chief Medical Officer
5,000   Disposition at $116 per share. 580,000
11/18/2019 Marc E. Lippman
Director
17,500   Derivative/Non-derivative trans. at $12.76 per share. 223,300
11/18/2019 Marc E. Lippman
Director
17,500   Derivative/Non-derivative trans. at $19.02 per share. 332,850
11/18/2019 Roger D. Dansey
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $65.11 per share. 325,550
11/08/2019 Clay B. Siegall
President and CEO; Director
20,799   Disposition at $108.08 per share. 2,247,955
11/08/2019 Clay B. Siegall
President and CEO; Director
3,968   Disposition at $107.32 per share. 425,845
11/08/2019 Clay B. Siegall
President and CEO; Director
2,120   Disposition at $105.93 per share. 224,571
11/08/2019 Clay B. Siegall
President and CEO; Director
1,585   Disposition at $104.38 per share. 165,442
11/08/2019 Clay B. Siegall
President and CEO; Director
20,799   Derivative/Non-derivative trans. at $12 per share. 249,588
11/08/2019 Clay B. Siegall
President and CEO; Director
3,968   Derivative/Non-derivative trans. at $12 per share. 47,616
11/08/2019 Clay B. Siegall
President and CEO; Director
2,120   Derivative/Non-derivative trans. at $12 per share. 25,440
11/08/2019 Clay B. Siegall
President and CEO; Director
1,585   Derivative/Non-derivative trans. at $12 per share. 19,020
10/08/2019 Clay B. Siegall
President and CEO; Director
14,420   Disposition at $82.01 per share. 1,182,584
10/08/2019 Clay B. Siegall
President and CEO; Director
13,352   Disposition at $82.89 per share. 1,106,747
10/08/2019 Clay B. Siegall
President and CEO; Director
700   Disposition at $83.9 per share. 58,730
10/08/2019 Clay B. Siegall
President and CEO; Director
14,420   Derivative/Non-derivative trans. at $12 per share. 173,040
10/08/2019 Clay B. Siegall
President and CEO; Director
13,352   Derivative/Non-derivative trans. at $12 per share. 160,224
10/08/2019 Clay B. Siegall
President and CEO; Director
700   Derivative/Non-derivative trans. at $12 per share. 8,400
10/01/2019 David W. Gryska
Director
2,500   Disposition at $84.85 per share. 212,125
10/01/2019 David W. Gryska
Director
2,500   Disposition at $85.33 per share. 213,325
10/01/2019 David W. Gryska
Director
2,500   Derivative/Non-derivative trans. at $12.76 per share. 31,900
10/01/2019 David W. Gryska
Director
2,500   Derivative/Non-derivative trans. at $19.02 per share. 47,550
09/30/2019 Todd E. Simpson
Chief Financial Officer
15,000   Disposition at $85 per share. 1,275,000
09/30/2019 Jean I. Liu
GC/EVP, Leg Affairs
3,716   Disposition at $85 per share. 315,860
09/30/2019 Jean I. Liu
GC/EVP, Leg Affairs
3,716   Disposition at $87 per share. 323,292
09/25/2019 Roger D. Dansey
Chief Medical Officer
490   Disposition at $74.24 per share. 36,377
09/25/2019 Roger D. Dansey
Chief Medical Officer
2,510   Disposition at $73.72 per share. 185,037

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
21 Purchases
27 Sales
160,916
186,348
Last 6 months
41 Purchases
55 Sales
387,860
361,352
Last 12 months
83 Purchases
89 Sales
760,495
1,536,098

Officers and Executives

Dr. Clay B. Siegall
Chairman, President & Chief Executive Officer
Mr. Todd E. Simpson
Chief Financial & Accounting Officer
Dr. Roger D. Dansey
Chief Medical Officer
Dr. Vaughn B. Himes
Chief Technical Officer
Dr. Robert J. Lechleider
Senior Vice President-Clinical Development
Ms. Natasha A. Hernday
Senior Vice President-Corporate Development
Dr. Robin G. Taylor
Chief Commercial Officer
Dr. Dennis Benjamin
Senior Vice President-Translational Research
Dr. Peter D. Senter
Vice President-Chemistry
Ms. Brandi Robinson
Media Contact
Ms. Tricia Larson
Media Contact
Ms. Peggy Pinkston
Vice President-Investor Relations
Mr. Christopher Pawlowicz
Executive Vice President-Human Resources
Ms. Jean I. Liu
Executive VP-Legal Affairs & General Counsel
Dr. Alpna Seth
Independent Director
Dr. Marc E. Lippman
Independent Director
Mr. John A. Orwin
Independent Director
Dr. Srinivas Akkaraju
Independent Director
Mr. David W. Gryska
Independent Director
Dr. Felix James Baker
Lead Independent Director
Mr. Daniel G. Welch
Independent Director
Dr. Nancy A. Simonian
Independent Director
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.